the versatility of the health economic working group on the types of information used is a key element in the decision-making process. In addition to the use of health economic evaluation, other factors such as social val- ues as in the case of imiglucerase come into play, which raised the legitimacy of the decision-making process as well as reduced resistance from stakeholders, especially patients and physicians.